ArticlePneumonia (Nathan Qld.)2025
Identification of age-group reservoirs for persistent vaccine-type pneumococcal carriage in rural Gambia.
Article in Pneumonia (Nathan Qld.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAlthough pneumococcal conjugate vaccines (PCVs) have been used widely in many low and middle-income countries, residual vaccine-type (VT) carriage persists in these settings. We examined the role of specific age groups in transmission and as reservoirs of VT pneumococcal infection in The Gambia.
methodsBetween January and November 2022, we conducted a nested, population-based, cross-sectional social contact and pneumococcal carriage survey in the Central and Upper River Regions of The Gambia. Participants completed questionnaires on carriage risk factors and social contacts. Nasopharyngeal swabs were collected from selected household members across all age groups. Streptococcus pneumoniae was isolated and serotyped using standard methods. We analysed matched contact and pneumococcal carriage data and estimated the proportions of VT carriage attributable to contact with different age groups.
resultsA total of 1638 participants were enrolled, of which 67% were children aged 0-14 years. Pneumococcal carriage prevalence was 59.6% (95% CI: 53.9 - 65.1%) in 0-4 year-olds and 36.1% (95% CI: 29.6 - 43.1%) in 5-14 year-olds. PCV13 VT carriage prevalence was not significantly different (10-13%) between these age groups. Among pneumococcal carriers, the proportion of VT carriage was significantly higher in 5- 14-year-olds [35.7% (95% CI: 25.9 - 46.9%)] compared to 0-4-year-olds [17.8% (95% CI: 13.9 - 22.6%, p-value < 0.001)]. The odds of VT carriage were 10% higher [AOR = 1.10, 95% CI: 1.01-1.20] for each additional physical contact with a child aged 10-14 years. We estimated that children aged 5-14 years contributed about 63% to the overall risk of exposure to VT pneumococci in the population.
conclusionsIn rural Gambia, school-aged children, particularly those aged 5-9 years, are the main drivers of VT pneumococcal transmission. In the context of high coverage of routine PCV vaccination in infants, this suggests waning PCV protection by school entry. A booster dose for children at school entry may support better control of VT circulation in the population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.